- Home
- DXR vs LVTX Comparison
DXR vs LVTX Comparison
Compare DXR & LVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXR
- LVTX
- Stock Information
- Founded
- DXR 1970
- LVTX 2016
- Country
- DXR United States
- LVTX Netherlands
- Employees
- DXR N/A
- LVTX N/A
- Industry
- DXR Medical/Dental Instruments
- LVTX Biotechnology: Pharmaceutical Preparations
- Sector
- DXR Health Care
- LVTX Health Care
- Exchange
- DXR Nasdaq
- LVTX Nasdaq
- Market Cap
- DXR 36.4M
- LVTX 33.9M
- IPO Year
- DXR N/A
- LVTX 2021
- Fundamental
- Price
- DXR $9.49
- LVTX $1.32
- Analyst Decision
- DXR Strong Buy
- LVTX Hold
- Analyst Count
- DXR 1
- LVTX 3
- Target Price
- DXR $25.00
- LVTX $1.75
- AVG Volume (30 Days)
- DXR 5.6K
- LVTX 34.7K
- Earning Date
- DXR 01-01-0001
- LVTX 08-19-2025
- Dividend Yield
- DXR N/A
- LVTX N/A
- EPS Growth
- DXR 86.16
- LVTX N/A
- EPS
- DXR 0.11
- LVTX N/A
- Revenue
- DXR $119,714.00
- LVTX $4,990,000.00
- Revenue This Year
- DXR N/A
- LVTX N/A
- Revenue Next Year
- DXR N/A
- LVTX N/A
- P/E Ratio
- DXR $82.80
- LVTX N/A
- Revenue Growth
- DXR N/A
- LVTX N/A
- 52 Week Low
- DXR $6.55
- LVTX $0.85
- 52 Week High
- DXR $10.00
- LVTX $2.39
- Technical
- Relative Strength Index (RSI)
- DXR 69.88
- LVTX 49.61
- Support Level
- DXR $8.68
- LVTX $1.28
- Resistance Level
- DXR $9.03
- LVTX $1.38
- Average True Range (ATR)
- DXR 0.47
- LVTX 0.05
- MACD
- DXR 0.03
- LVTX -0.00
- Stochastic Oscillator
- DXR 90.38
- LVTX 26.92
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
About LVTX LAVA Therapeutics N.V.
LAVA Therapeutics NV isa clinical stage immuno-oncology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer. Company's pipeline include's products such as LAVA-1266, LAVA-1427, LAVA-1433, LAVA-1207, PF08046052, JNJ89853413.